By playing, you agree to uListen's Terms and Privacy Policy and YouTube's Terms of Service.
Summaries, chapters, transcripts, and FAQs on this page are made by uListen, not YouTube.
CHAPTERS
- 0:02 – 5:54
David Nutt's Early Fascination with the Brain and Psychiatry
David Nutt explains how a childhood curiosity about thinking led him from physiology and neurology to psychiatry. Peter Attia shares his six-year-old son's question about how a brain produces thoughts, and Nutt recounts his first psychiatric patient, who had olfactory hallucinations.
- •Nutt realized as a small child that thinking comes from the brain and has been fascinated ever since
- •He moved from physiology to neurology to psychiatry, which he found wonderful because it shows every aspect of the brain
- •His forthcoming book, Brain and Mind Made Simple, explains how many nerves give rise to consciousness
- •His first patient was psychotic and hallucinated a smell of fish, linked to temporal lobe disorders
- 5:54 – 11:20
From Neuropsychopharmacology to Government Drug Policy
Nutt describes how the shift from seeing the brain as electrical to chemical shaped his career in neuropsychopharmacology. He then recounts being asked to advise the British government on drug policy, work on ecstasy harms, and being sacked when evidence clashed with politics, with Attia asking about US influence.
- •The early 1970s revelation that the brain is a chemical organ drove his interest in drugs as research tools
- •He was asked to help justify drug policy but found it was not evidence-based, and was sacked
- •Ecstasy harms came largely from dehydration and overheating, leading to free water and chill-out rooms in clubs
- •Nutt says every British drug law until 2016 was made at the behest of the Americans, with the war on drugs driven by US politics
- 11:20 – 19:08
A Multi-Criteria Framework for Ranking Drug Harms
Attia proposes a framework of harm, addictiveness and dependence, and Nutt describes the 16-criterion multi-criteria decision analysis used in Britain, Europe and Australia. Alcohol ranks most harmful overall, while opiates, crack and crystal meth are worst for the user; tobacco and the benefits of alcohol are also discussed.
- •Nutt's analysis uses nine harms to the user and seven harms to society, weighted
- •Alcohol is the most harmful overall because of its harms to others, but is about fourth for harm to the user
- •Opiates, crack cocaine and crystal meth are most harmful to the user
- •Tobacco ranked lower than alcohol in his analysis because it kills later in life and harms others less
- •Alcohol's powerful social benefits help explain its long stability in society
- 19:08 – 23:35
Cannabis vs. Alcohol and the Missing Research
Attia asks whether society's social dependence on alcohol explains why cannabis is illegal, and Nutt offers his own view about decades of disinformation. They discuss how federal funding rules blocked research on cannabis benefits and harms, even after California legalized medical cannabis.
- •Nutt notes cannabis is not a particularly social drug, but he attributes its vilification to the alcohol industry and the DEA
- •Attia is frustrated he cannot answer patients' questions about teen cannabis use and brain development
- •Nutt says NIDA has not been funded to study benefits, and federal illegality prevented research funding
- •He calls this one of many perverse consequences of the prohibitionist approach
- 23:35 – 26:37
Harm Rankings for Psychedelics and Mechanisms of Opioid Death
Attia asks where psychedelics and MDMA fit in the harm ranking, and Nutt says the most vilified drugs turned out the least dangerous. They then narrow to harm to the individual, ranking opioids, crystal and crack, and note that opioids kill through respiratory depression.
- •Magic mushrooms, LSD and MDMA rank least harmful, while alcohol ranks most harmful overall
- •Nutt says he had been lied to about drug harms when he began government work
- •For harm to the user the order is opioids, crystal meth, then crack
- •Opioids kill through overdose and respiratory depression, often when heroin is spiked with fentanyl
- 26:37 – 30:49
The Fentanyl Crisis: A Perfect Storm
Nutt walks through how overprescription of opioids, a reaction that cut off prescriptions, and international poppy limits pushed users to a black market flooded with fentanyl. He proposes drug testing and alternatives such as medical cannabis for chronic pain.
- •Heavily promoted morphine-derivative painkillers and prescribing for chronic pain started the cycle
- •Stopping prescriptions pushed dependent patients to heroin and fentanyl from the black market
- •Mexican cartels moved to fentanyls, which Nutt says are 50 times more potent than heroin and cheaper to make, with carfentanil a thousand times more potent
- •His proposed solutions are widespread drug testing, eliminating fentanyls and safer pain treatments like medical cannabis
- 30:49 – 41:33
Ibogaine, the Default Mode Network and Why People Get Addicted
Attia raises ibogaine for opioid addiction, and Nutt describes planned imaging work and cardiac risk concerns. The conversation moves to how psychedelics may disrupt the default mode network, and to the social and personal factors behind addiction.
- •Nutt's team hopes to study noribogaine, which may be less cardiotoxic, with cardiac monitoring in a hospital
- •He does not think ibogaine should be given during withdrawal
- •Psychedelics disrupt the default mode network, where the sense of self and entrenched habits like depression or addiction are embedded
- •Addiction involves social factors, coping with stress, and for some people a feeling of being whole only on a drug
- 41:33 – 48:38
Cocaine: Mechanism, Risks and Attia's Two-Lever Framework
Nutt covers cocaine's history, including Freud's use, and its effects through dopamine and noradrenaline release, along with cardiac risk and cocaethylene. Attia presents his own framework of physical risk and state versus trait change, and the Len Bias case is discussed.
- •Freud thought cocaine could help get people off heroin but became dependent himself
- •Cocaine acts via dopamine and noradrenaline release, and mixing it with alcohol produces more cardiotoxic cocaethylene
- •Attia judges drugs by physical risk and whether they alter a trait rather than just a state, concluding cocaine fails both
- •Nutt agrees about crack but thinks occasional cocaine use may be manageable without cardiac problems
- •Len Bias's death is discussed as a spur to the war on drugs
- 48:38 – 53:13
Methamphetamine: History, War and Neurotoxicity
Nutt traces amphetamine from an asthma treatment through its use by soldiers in the Second World War, contrasting Allied amphetamine sulfate with longer-acting methamphetamine. He discusses how meth depletes and distorts dopamine pathways, while cautioning that evidence of brain damage comes largely from heavy post-war Japanese use.
- •Amphetamines were developed as a synthetic alternative to ephedra for asthma
- •Allied troops used amphetamine sulfate while Germans and Japanese used longer-lasting methylamphetamine, leading to sleep deprivation and paranoia
- •Meth pushes the dopamine system toward depletion and may impair frontal executive function
- •Evidence of brain damage is strongest from heavy intravenous use in post-war Japan
- 53:13 – 1:04:45
How LSD Was Banned and What Early Research Showed
Attia notes the Schedule 1 criteria and Nutt argues LSD was banned for political and social reasons tied to the anti-war counterculture rather than harm. He describes the large body of earlier research, UK and US treatment approaches, and the potential for alcoholism treatment.
- •Nutt says LSD was banned amid the hippie movement and opposition to the Vietnam War, with invented social harm stories
- •Earlier research covered 40,000 patients and a thousand papers showing safety and effectiveness
- •US therapy used big doses with psychotherapy, while UK therapists used repeated lower doses
- •A meta-analysis of old LSD alcoholism trials showed an effect size of one, which Nutt calls twice that of later treatments
- •Nutt calls the ban the worst censorship of research in history
- 1:04:45 – 1:09:46
Psilocybin, Magic Mushrooms and the UK Ban
Nutt discusses the history of psilocybin and magic mushrooms, why his team chose psilocybin for research, and how UK mushrooms were banned in 2005. He ties the ban to political expediency after freeze-dried mushrooms were sold in London head shops.
- •Psilocybin lacks the stigma of LSD with politicians
- •UK mushrooms were legal until 2005, and the safety record from heavy youth use helped win regulatory permission
- •Psilocybin was banned in 1971 alongside LSD but the mushrooms themselves were not
- •A head shop controversy and political pressure on Tony Blair led to the mushroom ban
- 1:09:46 – 1:14:28
MDMA: Origins, Demonization and the Retracted-Style Monkey Study
Attia and Nutt place MDMA as an empathogen, and Nutt recounts Sasha Shulgin's discovery and its use in therapy before it was rebranded as ecstasy. He describes the bad science used to justify its ban, including a monkey study that used methamphetamine instead.
- •Shulgin found MDMA gave clarity and empathy rather than amphetamine-like drive
- •Therapists used it for about 10 years before it was renamed ecstasy and sold recreationally
- •Banning required evidence of harm, leading to flawed brain damage claims
- •The monkey study in Science actually used methamphetamine, and Nutt says it was corrected rather than struck out
- •Nutt argues such deception makes young people distrust government advice
- 1:14:28 – 1:21:29
Ketamine, Esketamine and Tolerance to Psychedelics
Nutt explains how ketamine's antidepressant effect was discovered, why esketamine was developed, and the risks of heavy recreational use such as bladder damage and cognitive impairment. They discuss tachyphylaxis, noting that with ketamine tolerance can be overcome with more drug but not with psychedelics.
- •John Krystal noticed improved mood in volunteers after ketamine and it was studied for depression
- •The effect lasts only two or three days, and esketamine was patented as a nasal spray
- •Heavy ketamine use causes severe cystitis and cognitive impairment, and daily use is too much
- •Tolerance to psychedelics builds within days and fades over one to two weeks, and cannot be overcome with higher doses
- 1:21:29 – 1:40:33
Psilocybin vs. Lexapro in Depression and Microdosing
Nutt describes the study comparing psilocybin with escitalopram, its design, results and how journal rules shaped the framing. They then discuss microdosing, the lack of controlled research, and the prospects for rescheduling, including Compass Pathways and Oregon.
- •The trial used a blinded design with low-dose and high-dose psilocybin, and psilocybin matched escitalopram on the primary measure
- •Psilocybin did better on secondary measures such as wellbeing and sexual dysfunction, but the primary-outcome rules limited reporting
- •Nutt says no proper controlled microdosing study has been done because of Schedule 1 restrictions
- •He expects depression to be the first domino, citing the Compass Pathways dose-finding study
- •He sees a race between Compass and Oregon, where the mushroom itself may become the medicine
